PRFX
What one share of PRF Technologies holds
Pharmaceutical Preparations
We are a specialty pharmaceutical company focused on the reformulation of established therapeutics. Our proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.
PRF Technologies’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.03 |
|---|---|
| Profit | −$7.47 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$6.11 |
| Cash and investments | $3.76 |
| Book value | $10.29 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$3.25 | — | −$1.10 | — | −$19.21 |
| 2019 | — | −$4.18 | $0.00 | −$1.06 | — | −$21.23 |
| 2020 | — | −$1.25 | $0.00 | −$0.79 | — | — |
| 2021 | — | −$7.25 | $0.05 | −$6.61 | — | — |
| 2022 | — | −$63.46 | $0.04 | −$46.66 | — | — |
| 2023 | $0.00 | −$122.94 | $0.12 | −$87.99 | — | — |
| 2024 | $0.00 | −$105.52 | $0.09 | −$91.38 | — | — |
| 2025 | $0.03 | −$7.47 | $0.00 | −$6.11 | — | $10.29 |